Comparison of Serum Malondialdehyde and Paraoxonase-1 Levels in Patients with Epilepsy with and without Status Epilepticus

Year 2023, Volume: 13 Issue: 1, 18 - 23, 26.04.2023

Ahmet Dündar Demet Arslan Gülsüm Çelik Uysal Ahmet Yılmaz

Abstract

Aim: The underlying pathophysiological mechanisms in epilepsy are still not fully known. Paraoxonase (PON)-1 activity and malondialdehyde (MDA) levels are biomarkers used in the measurement of oxidative stress. Studies show that oxidative stress has a role in the pathophysiology of epilepsy. The aim of our study is to evaluate serum PON-1 activity and MDA levels in epilepsy patients with and without status epilepticus (SE).
Materials and Method: The subjects included in the study were established in two groups. Group I: The patient diagnosed with status epilepticus (n=30), group II: 30 adult patients with epilepsy who were in the outpatient policlinic follow-up and were not in status were included in the study. Serum MDA levels and PON-1 activity were measured by spectrophotometric method in the biochemistry laboratory.
Results: Serum MDA levels were found to be 86.8±32.4 nmol/ mL in patients with SE and 65.8±15.7 nmol/mL in patients without SE. Serum PON-1 activity was 180.8±28.3 U/L in patients with SE and 170.2±25.0 U/L in patients without SE. When patients with SE and patients without SE were compared, serum MDA levels were found to be higher than patients without SE and statistically significant (p<0.001). There was no significant difference between the two patient groups in terms of PON-1 activity (p>0.05).
Conclusion: The results of our study indicate that the oxidant/ antioxidant balance in the pathogenesis of status epilepticus has deteriorated in favor of oxidative stress and the antioxidant system cannot give an adequate response. Larger research should be conducted to evaluate the use of serum MDA levels as a biomarker.

Keywords

status epilepticus, MDA, PON-1, antioxidant/oxidant status

References

• 1. Abdel-Salam OME, Sleem AA, Sayed MAEBM, Youness ER, Shaffie N. Capsaicin exerts anti-convulsant and neuroprotective effects in pentylene tetrazole-induced seizures. Neurochem Res. 2020; 45(5):1045–1061.
• 2. Lin TK, Chen SD, Lin KJ, Chuang YC. Seizure-induced oxidative stress in status epilepticus: is antioxidant beneficial? Antioxidants (Basel). 2020; 9(11):1029.
• 3. Santos LF, Freitas RL, Xavier SM, Saldanha GB, Freitas RM. Neuroprotective actions of vitamin C related to decreased lipid peroxidation and increased catalase activity in adult rats after pilocarpine-induced seizures. Pharmacol Biochem Behav. 2008; 89(1):1–5.
• 4. Shekh-Ahmad T, Kovac S, Abramov AY, Walker MC. Reactive oxygen species in status epilepticus. Epilepsy Behav. 2019; 101(Pt B):106410.
• 5. Freitas RM, Vasconcelos SM, Souza FC, Viana GS, Fonteles MM. Oxidative stress in the hippocampus after pilocarpine-induced status epilepticus in Wistar rats. FEBS J. 2005; 272(6):1307–12.
• 6. Abuja PM, Albertini R. Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins. Clin Chim Acta. 2001; 306(1-2):1–17.
• 7. Gawel SH, Davis GJ, Luo M, Deutz NEP, Wolfe RR, Pereira SL. Serum biomarkers that predict lean mass loss over bed rest in older adults: An exploratory study. Clin Chim Acta. 2020; 509:72–78.
• 8. Lyon FR. Re-evaluation of some organic chemicals, hydrazine and hydrogen peroxide international agency for research on cancer. IARC Monogr Eval Carcinog Risks Hum. 1999; 71 Pt 1(PT 1):1–315.
• 9. Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis. 2005; 15(4):316–28.
• 10. Gaschler MM, Stockwell BR. Lipid peroxidation in cell death. Biochem Biophys Res Commun. 2017; 482(3):419–425. 11. Altınkaynak Y, Örem A, Altınkaynak BA, Kural B, Balaban Yücesan F, Örem C. Investigation of serum paraoxonase 1 (PON1) activity in postprandial lipemia. Acta Med Alanya. 2018; 3(1):3–11.
• 12. Nguyen SD, Sok DE. Preferential inhibition of paraoxonase activity of human paraoxonase 1 by negatively charged lipids. J Lipid Res. 2004; 45(12):2211–20.
• 13. Bednarz-Misa I, Berdowska I, Zboch M, Misiak B, Zieliński B, Płaczkowska S, et al. Paraoxonase 1 decline and lipid peroxidation rise reflect a degree of brain atrophy and vascular impairment in dementia. Adv Clin Exp Med. 2020; 29(1):71–78.
• 14. Saeidi M, Shakeri R, Marjani A, Khajeniazi S. Alzheimer’s disease and paraoxonase 1 (pon1) gene polymorphisms. Open Biochem J. 2017; 11:47–55.
• 15. Boado RJ, Zhang Y, Zhang Y, Wang Y, Pardridge WM. IgGparaoxonase-1 fusion protein for targeted drug delivery across the human blood-brain barrier. Mol Pharm. 2008; 5(6):1037–43.
• 16. Nguyen SD, Sok DE. Oxidative inactivation of paraoxonase 1, an antioxidant protein and its effect on antioxidant action. Free Radic Res. 2003; 37(12):1319–30.
• 17. Karikas GA, Schulpis KH, Bartzeliotou A, Regoutas S, Thanopoulou C, Papaevangelou V, et al. Early effects of sodium valproate monotherapy on serum paraoxonase/arylesterase activities. Scand J Clin Lab Invest. 2009; 69(1):31–5.
• 18. Yüksel A, Cengiz M, Seven M, Ulutin T. Erythrocyte glutathione, glutathione peroxidase, superoxide dismutase and serum lipid peroxidation in epileptic children with valproate and carbamazepine monotherapy. J Basic Clin Physiol Pharmacol. 2000; 11(1):73–81.
• 19. Yüksel A, Cengiz M, Seven M, Ulutin T. Changes in the antioxidant system in epileptic children receiving antiepileptic drugs: two-year prospective studies. J Child Neurol. 2001; 16(8):603–6.
• 20. Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the international league against epilepsy: Position paper of the ILAE commission for classification and terminology. Epilepsia. 2017; 58(4):522–530.
• 21. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983; 35(6):1126–38.
• 22. Eckerson HW, Romson J, Wyte C, La Du BN. The human paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet. 1983; 35(2):214–27.
• 23. Islam MR. Sample size and its role in central limit theorem (CLT). Computational and Applied Mathematics Journal. 2018; 4(1):1–7.
• 24. Freitas RM. Investigation of oxidative stress involvement in hippocampus in epilepsy model induced by pilocarpine. Neurosci Lett. 2009; 462(3):225–9.
• 25. Carmona-Aparicio L, Zavala-Tecuapetla C, González-Trujano ME, Sampieri AI, Montesinos-Correa H, Granados-Rojas L, et al. Status epilepticus: Using antioxidant agents as alternative therapies. Exp Ther Med. 2016; 12(4):1957–1962.
• 26. Ramaekers VT, Bosman B, Jansen GA, Wanders RJ. Increased plasma malondialdehyde associated with cerebellar structural defects. Arch Dis Child. 1997; 77(3):231–4.
• 27. Alachkar A, Azimullah S, Ojha SK, Beiram R, Łażewska D, Kieć-Kononowicz K, et al. The neuroprotective effects of histamine h3 receptor antagonist e177 on pilocarpine-induced status epilepticus in rats. Molecules. 2019; 24(22):4106.
• 28. Garin MC, Kalix B, Morabia A, James RW. Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome. J Clin Endocrinol Metab. 2005; 90(4):2264–9.
• 29. Shunmoogam N, Naidoo P, Chilton R. Paraoxonase (PON)1: A brief overview on genetics, structure, polymorphisms and clinical relevance. Vasc Health Risk Manag. 2018; 14:137–143.
• 30. Dönmezdil N, Çevik MU, Özdemir HH, Taşin M. Investigation of PON-1 activity and MDA levels in patients with epilepsy not receiving antiepileptic treatment. Neuropsychiatr Dis Treat. 2016; 12:1013–7.
• 31. Çevik MU, Varol S, Yücel Y, Akıl E, Çelepkolu T, Arıkanoğlu A, et al. Epilepsili hastalarda serum paraoksonaz-1 aktivitesi ve malondialdehit düzeyleri. Dicle Tıp Dergisi. 2012; 39 (4):557560.
• 32. Marrocco I, Altieri F, Peluso I. Measurement and clinical significance of biomarkers of oxidative stress in humans.Oxid Med Cell Longev. 2017; 2017:6501046.
• 33. Togha M, Razeghi Jahromi S, Ghorbani Z, Ghaemi A, Rafiee P. An investigation of oxidant/antioxidant balance in patients with migraine: a case-control study. BMC Neurol. 2019; 19(1):323.
• 34. Schreibelt G, van Horssen J, van Rossum S, Dijkstra CD, Drukarch B, de Vries HE. Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology. Brain Res Rev. 2007; (2):322–30.
• 35. Menon B, Ramalingam K, Kumar R. Evaluating the role of oxidative stress in acute ischemic stroke. J Neurosci Rural Pract. 2020; 11(1):156–159.
• 36. Verrotti A, Scardapane A, Franzoni E, Manco R, Chiarelli F. Increased oxidative stress in epileptic children treated with valproic acid. Epilepsy Res. 2008; 78(2-3):171–7.
• 37. Tong V, Teng XW, Chang TK, Abbott FS. Valproic acid I. time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats. Toxicol Sci. 2005; 86(2):427–435.
• 38. Hamed SA, Abdellah MM. Trace elements and electrolytes homeostasis and their relation to antioxidant enzyme activity in brain hyperexcitability of epileptic patients. Journal of Pharmacological Sciences. 2004; 96(4):349–59.
• 39. Das A, Sarwar MS, Hossain MS, Karmakar P, Islam MS, Hussain ME, et al. Elevated serum lipid peroxidation and reduced vitamin C and trace element concentrations are correlated with epilepsy. Clin EEG Neurosci. 2019; 50(1):63–72.
• 40. Menon B, Ramalingam K, Kumar RV. Oxidative stress in patients with epilepsy is independent of antiepileptic drugs. Seizure. 2012; 21(10):780–4.
• 41. Pandey MK, Mittra P, Maheshwari PK. The lipid peroxidation product as a marker of oxidative stress in epilepsy. J Clin Diagn Res. 2012; 6(4):590–92.
• 42. Wojciech S, Elzbieta S, Wojciech K. Evaluation of the influence of the antiepileptic therapy on the antioxidant enzyme activity and the lipid peroxidation in the erythrocytes of children with epilepsy. J Child Neurol. 2006; 21(7):558–62